Streamlining Hepatitis C Treatment: Implementation of a Clinical Pharmacist‐Driven Medication Management Program
- 10 November 2026
- journal article
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (12)
Abstract
Background: Hepatitis C virus (HCV) affects over 3.9 million individuals in the United States and is effectively treated with direct‐acting antiviral (DAA) agents. Clinical pharmacists (CPs) may be the ideal provider to bridge gaps in HCV care by selecting appropriate therapy following drug–drug interaction (DDI) review, navigating access barriers, and supporting adherence. Although CP involvement in HCV care has demonstrated clinical value, there is limited literature describing CP workflows, patient interventions, and CP‐led programs that support patients from treatment initiation through sustained virologic response at 12 weeks (SVR12). This study aims to quantify and categorize CP‐driven enrollments in a Hepatitis C Clinical Program (HCCP) and assess its impact on patient safety, operational, and clinical outcomes. Methods: This retrospective descriptive study evaluates a CP‐driven HCCP within a health system specialty pharmacy (HSSP) from May 6, 2024 to March 6, 2025. Patients with a referral to the CP for HCV treatment selection, or external patients with a DAA claim at the HSSP, were eligible for enrollment in the program. The HCCP consisted of six points of clinical care: CP therapy selection, medication access and order placement, prescription triage and patient education, follow‐up throughout treatment, intervention support, and laboratory monitoring through SVR12. Results: A total of 122 patients were enrolled in the HCCP. Most patients were treatment‐naïve (90%) and non‐cirrhotic (79%). DDIs were identified in 57% of patients, with statin therapy being the most common (46%). Time‐to‐treatment was 4 days or less for 76% of patients, with an 88% HSSP prescription capture rate. A 97% SVR12 rate was achieved, and 92% of patients completed therapy on time. Conclusion: This study highlights the role of the CP in HCV care and their impact on patient safety and clinical and operational outcomes. Results support further development of CP‐driven practice changes and support the implementation of a similar program within other HSSPs.This publication has 13 references indexed in Scilit:
- Lifetime medical costs of chronic hepatitis C in the United StatesBMC Health Services Research, 2026
- Estimating hepatitis C prevalence in the United States, 2017–2020Hepatology, 2024
- Impact of pharmacist-driven referral to increase specialty pharmacy prescription captureAmerican Journal of Health-System Pharmacy, 2024
- Estimated Prevalence and Awareness of Hepatitis C Virus Infection Among US Adults: National Health and Nutrition Examination Survey, January 2017–March 2020Clinical Infectious Diseases, 2023
- Patient Access to Hepatitis C Treatment After Incorporation of Pharmacists in a Hepatology ClinicHospital Pharmacy, 2021
- Evaluation of a specialty hepatitis C virus telephone pharmacy serviceAmerican Journal of Health-System Pharmacy, 2021
- Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist–Driven ModelOpen Forum Infectious Diseases, 2019
- Local specialty pharmacy and specialty clinic collaboration assists access to hepatitis C direct-acting antiviralsJournal of the American Pharmacists Association, 2018
- Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of InsuranceClinical Gastroenterology and Hepatology, 2016
- Hepatitis C Virus Genotypes and Viral Concentrations in Participants of a General Population Survey in the United StatesGastroenterology, 2006